Count Me In! China To Update Drug Coverage After Long Wait
After a long seven-year hiatus, China is finally moving to update its national reimbursement drug list, but the process will involve huge numbers of experts and the benefits of inclusion may not be as immediate or as extensive as appear at first sight.
You may also be interested in...
With portfolios well-matched to market needs, there are no expectations of a slowdown in the near future for Pfizer in China. The company will continue to be “opportunistic” in making investments to drive its business there.
Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.